Abstract
The article by Hulka et al (p 475) in this issue ofThe JOURNALsuggests a halving of the relative risk of endometrial cancer in women, on reaching an average age of 50 years, who were taking a combination birth control pill at the time of the study. This is consonant with other reports that suggest a beneficial effect of progestins in moderating cancer risk from exogenous or endogenous estrogens. It is important to point out what the health care implications of such an observation might be for women in this age group. The data from this case-control study indicate what the relative benefit might be in reduction of endometrial cancer, but do not reveal the number of subjects at risk for such malignancy or the risk of oral contraceptive (OC) use that can be derived from a different type of epidemiological survey. The incidence of endometrial cancer in women
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
